Cyprus Mail on MSN

Travere wins FSGS approval for FILSPARI, a milestone for holders including Armistice Capital

Travere Therapeutics spent the first half of 2026 converting a single approved medicine into a broader commercial and pipeline story. A rare-disease drugmaker built around FILSPARI, its treatment for ...

Guggenheim Reaffirms Their Buy Rating on Insmed (INSM)

In a report released today, Vamil Divan from Guggenheim maintained a Buy rating on Insmed, with a price target of $207.00. Claim 55% Off TipRanks. Unlock powerful investing tools ...

Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?

NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, ...

The American Kidney Fund and IgA Nephropathy Foundation Create New IgA Nephropathy Patient Guidelines (UPDATE)

Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation announce the creation of a new resource for IgA nephropathy patients and their loved ones: the IgA nephropathy patient ...

Analysts Conflicted on These Healthcare Names: Zura Bio (ZURA), Insmed (INSM) and Harmony Biosciences Holdings (HRMY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zura Bio , Insmed and Harmony Biosciences Holdings . TipRanks Welcomes a New ETF ...

Travere Therapeutics Inc.

Travere Therapeutics Inc. company and executive profile by Barron's. View the latest TVTX company infomation and executive bios.
Fierce Pharma

Novartis gains full FDA nod for Fabhalta in kidney disorder IgAN

With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3 testing, ...